Ticker Details
MannKind Corporation MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
IPO Date:	July 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.28B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 3.49%
Avg Daily Range (30 D):	$0.11 | 2.78%
Avg Daily Range (90 D):	$0.09 | 2.93%

Institutional Daily Volume
Avg Daily Volume:	2.34M
Avg Daily Volume (30 D):	4.19M
Avg Daily Volume (90 D):	4.75M

Trade Size
Avg Trade Size (Sh.):	247
Avg Trade Size (Sh.) (30 D):	222
Avg Trade Size (Sh.) (90 D):	238

Institutional Trades
Total Institutional Trades:	3,994
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$3.9M
Avg Institutional Trade (90 D):	$2.61M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.94M
Avg Closing Trade (30 D):	$4.55M
Avg Closing Trade (90 D):	$3.03M
Avg Closing Volume:	397.97K

News

Jun 5, 2026 @ 11:35 PM Data at ADA 2026 Highlights Key Findings from Clin... Source: Mannkind Corporation

May 29, 2026 @ 6:00 PM MannKind to Host Conference Call Today to Discuss ... Source: Na

May 27, 2026 @ 8:00 PM MannKind to Present at Jefferies Global Healthcare... Source: Na

May 12, 2026 @ 2:30 PM The $59B Quiet Shift Reshaping How Patients Access... Source: Equity Insider

Mar 18, 2026 @ 2:00 PM A Key "Master" Protein That Declines by Half After... Source: Equity-Insider.Com

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.07	$-.05	$-.05
Diluted EPS	$-.07	$-.05	$-.05
Revenue	$360.78M	$90.17M	$111.96M
Gross Profit	$330.24M	$82.66M	$98.03M
Net Income / Loss	$-23.91M	$-16.62M	$-15.95M
Operating Income / Loss	$14.84M	$-1.67M	$-7.69M
Cost of Revenue	$30.54M	$7.51M	$13.93M
Net Cash Flow	$5.53M	$-22.05M	$-52.51M
PE Ratio

Splits
Mar 03, 2017	1:5